Enzastaurin hydrochloride.: Protein kinase C β inhibitor, antiangiogenic agent

被引：9
|
作者：
Sorbera, L. A. [1 ]
Serradell, N. [1 ]
Bolos, J. [1 ]
Rosa, E. [1 ]
机构：
[1] Prous Sci, Barcelona 08080, Spain
来源：
DRUGS OF THE FUTURE | 2007年 / 32卷 / 04期
关键词：
D O I：
10.1358/dof.2007.032.04.1095514
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protein kinase C (PKC) overexpression has been linked to several types of cancer, with the PKC beta isoform suspected to be involved in vascular endothelial growth factor (VEGF)-induced tumor development and angiogenesis and in the apoptosis-regulating phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Targeting of PKC beta therefore represents a potentially effective strategy for the treatment of cancer. Enzastaurin (LY-317615) is an acyclic bisindolylmaleimide that potently and selectively inhibits the PKC beta isoform. Enzastaurin displayed anticancer efficacy in several preclinical cancer models and in clinical trials in patients with advanced cancers. It is currently undergoing phase III development for relapsed glioblastoma multiforme and diffuse B-cell lymphoma.
引用
收藏
页码：297 / 309
页数：13
相关论文
共 50 条
  • [21] Enzastaurin (LY317615), an oral protein kinase C β inhibitor, induces apoptosis in multiple myeloma cell lines.
    Rizvi, MA
    Ghias, K
    Davies, KM
    Ma, C
    Krett, NL
    Rosen, ST
    BLOOD, 2005, 106 (11) : 452A - 453A
  • [22] The Protein Kinase C Beta Selective Inhibitor, Enzastaurin (LY317615), Enhances Anti-Angiogenic Effect of Radiation
    Willey, Christopher
    Xiao, Dakai
    Tu, Tianxiang
    Kim, Kwang Woon
    Moretti, Luigi
    Niermann, Kenneth
    Tawtawy, Mohammed
    Quarles, Chad
    Lu, Bo
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (06): : 614 - 614
  • [23] Enzastaurin, an inhibitor of PKCβ, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells
    Spalding, Aaron C.
    Zeitlin, Benjamin D.
    Wilder-Romans, Kari
    Davis, Mary E.
    Nor, Jacques E.
    Lawrence, Theodore S.
    Ben-Josef, Edgar
    TRANSLATIONAL ONCOLOGY, 2008, 1 (04): : 195 - U48
  • [24] Protein kinase inhibitor, enzastaurin, induces in vitro and in vivo antitumor activity in Waldenstrom S macroglobulinemia
    Moreau, A. S.
    Jia, X.
    Ngo, H.
    Leleu, X.
    Daley, J.
    Lalo, S.
    O'Sullivan, G.
    Roccaro, A.
    Hatjiharisi, E.
    Raab, M. S.
    Podar, K.
    D'Halluim, J. C.
    Facon, T.
    Treon, S.
    Hideshima, T.
    Anderson, K.
    Ghobrial, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 225 - 225
  • [25] Antiangiogenic effects of a protein kinase Cβ-selective small molecule
    Teicher, BA
    Alvarez, E
    Menon, K
    Esterman, MA
    Considine, E
    Shih, C
    Faul, MM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (01) : 69 - 77
  • [26] Antiangiogenic effects of a protein kinase Cβ-selective small molecule
    Beverly A. Teicher
    Enrique Alvarez
    Krishna Menon
    Michail A. Esterman
    Eileen Considine
    Chuan Shih
    Margaret M. Faul
    Cancer Chemotherapy and Pharmacology, 2002, 49 : 69 - 77
  • [27] The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin
    Bargagna-Mohan, Paola
    Hamza, Adel
    Kim, Yang-eon
    Ho, Yik Khuan
    Mor-Valknin, Nirit
    Wendschlag, Nicole
    Li, Junjun
    Evans, Robert M.
    Markovitz, David M.
    Zhan, Chang-Guo
    Kim, Kyung Bo
    Mohan, Royce
    CHEMISTRY & BIOLOGY, 2007, 14 (06): : 623 - 634
  • [28] Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C β-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer
    Rademaker-Lakhai, Jeany M.
    Beerepoot, Laurens V.
    Mehra, Niven
    Radema, Sandra A.
    van Maanen, Rianne
    Vermaat, Joost S.
    Witteveen, Els O.
    Visseren-Grul, Carla M.
    Musib, Luna
    Enas, Nathan
    van Hal, Gertjan
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Voest, Emile E.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4474 - 4481
  • [29] Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines
    Rizvi, Mujahid A.
    Ghias, Kulsoom
    Davies, Katharine M.
    Ma, Chunguang
    Weinberg, Frank
    Munshi, Hidayatullah G.
    Krett, Nancy L.
    Rosen, Steven T.
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (07) : 1783 - 1789
  • [30] The protein kinase Cβ-selective inhibitor, enzastaurin, attenuates amphetamine-stimulated locomotor activity and self-administration behaviors in rats
    Rachel D. Altshuler
    Colleen A. Carpenter
    Timothy J. Franke
    Margaret E. Gnegy
    Emily M. Jutkiewicz
    Psychopharmacology, 2019, 236 : 3231 - 3242
12345